Abstract Hormone receptor-positive (HR+) breast cancer is the most common type among women in the United States. Multigene assays such as Oncotype DX (ODX) assess recurrence risk and chemotherapy benefit but are costly and time-consuming. This exploratory study evaluates the AI-powered PreciseBreast (PDxBR) and compares its risk scoring with established tools. This pilot study was conducted in a community health system.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Robin
Contact Robin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack